Cellular Origins, a TTP company, focused on the robotic manufacture of cell and gene therapies (CGTs); the Cell and Gene Therapy Catapult (CGT Catapult), an independent organization specializing in CGT advancement; and Resolution Therapeutics, a clinical-stage biopharmaceutical company creating regenerative macrophage therapy to treat inflammatory and fibrotic diseases, announced on July 11, 2025 that the three organizations are forming a consortium that aims to use novel technologies to internationally deliver a unique, efficient, fully automated, and scalable cell therapy manufacturing platform. Source: Biopharma International 11/7/2025